摘要:
La présente invention concerne l'utilisation du 4-méthyl-2-oxo-2H-1-benzopyran-7-yl-5-thio-β-D-xylopyranoside dans le traitement d'une mucopolysaccharidose telle que la maladie de Maroteaux-Lamy.
摘要:
La présente invention concerne l'utilisation du 4-méthyl-2-oxo-2H-1-benzopyran-7-yl-5-thio-β-D-xylopyranoside dans le traitement des mucopolysaccharidoses.
摘要:
Provided are novel crystalline forms of Lanifibranor (Referred to as "Compound I") and preparation methods thereof, pharmaceutical compositions containing the crystalline forms, and uses of the crystalline forms for preparing pan-PPAR agonists drugs and drugs for treating NASH. Compared with prior arts, the provided crystalline forms of Compound I have one or more improved properties, which solve the problems of the prior art and is of great value to the optimization and development of the drugs.
摘要:
The invention relates to compounds of formula (I), where R, R 1 , R 2 n, A and Cy have the meanings indicated in the description. The compounds of formula (I) are Nurr-1 modulators.
摘要:
The invention relates to a drug combination and a method for the treatment of a liver disease, the combination comprising lanifibranor and firsocostat.
摘要:
The invention relates to the use of a pan-PPAR agonist, or of a pharmaceutical composition containing said agonist, for the treatment of a fibrotic condition.